Sign In
Buy IOVA
$4.07
-0.620 (-13.22%)
At Close: Jul 31, 2026
Iovance Biotherapeutics to Present at Upcoming Conference
08:05am, Thursday, 21'st May 2026
SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
12:11pm, Friday, 08'th May 2026
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity
10:58am, Friday, 08'th May 2026
Iovance Biotherapeutics, Inc. markets Amtagvi, a TIL therapy for advanced melanoma, and just reported Q1 earnings. Following Q1 results, IOVA shares declined over 13%, closing at $3.55, with a market
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
05:21pm, Thursday, 07'th May 2026
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Thursday, 07'th May 2026
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
07:05am, Thursday, 07'th May 2026
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street
02:30am, Saturday, 02'nd May 2026
It could just as well drop by 50% -- or more -- over the next 12 months.
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Thursday, 30'th Apr 2026
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
11:27am, Tuesday, 28'th Apr 2026
Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising effic
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
08:01am, Monday, 27'th Apr 2026
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 17'th Apr 2026
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?
12:30pm, Friday, 10'th Apr 2026
Iovance Biotherapeutics' most important product is generating rapidly growing sales. Between approvals in other countries and label expansions, it could maintain its momentum for a while.
Iovance Biotherapeutics, Inc. $IOVA Shares Purchased by Aberdeen Group plc
03:08am, Friday, 10'th Apr 2026
Aberdeen Group plc raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) by 25.1% during the undefined quarter, according to the company in its most recent 13F filing with the Sec
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving Average – Here’s What Happened
04:57am, Tuesday, 07'th Apr 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report)'s share price passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.42 and traded
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
10:05pm, Monday, 06'th Apr 2026
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73
